Research
Search
Close
ZHOU Yan
- Graduate Supervisor, Associate Chief Physician
- Department: Oncology
- Research Area: Oncology
- Research Interests: Osteosarcoma immune microenvironment
- Contact: 1987719zy@163.com
- MD from Shanghai Jiao Tong University of Medicine, 2023
- MPH from Shanghai Jiao Tong University of Medicine, 2014
- Associate Chief Physician, Department of Oncology, Shanghai Sixth People's Hospital
- Zhou Y, Li M, Zhang B, Yang C, Wang Y, Zheng S, Tang L, Zhou C, Qian G, Huang Y, Yu W, Li H, Wang Y, He A, Shen Z, Zhang J, Li X, Yang Q, Hu H, Yao Y. A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas. BMC Med, 2023, doi: 10.1186/s12916-023-03132-x.
- Ding X, Zhang Y, Liang J, Li Q, Hu H, Zhou Y#, Zhang B#. Dihydroartemisinin Potentiates VEGFR-TKIs Antitumorigenic Effect on Osteosarcoma by Regulating Loxl2/VEGFA Expression and Lipid Metabolism Pathway. J Cancer, 2023, doi: 10.7150/jca.81623.
- Zhou Y, Yang Q, Dong Y, Ji T, Zhang B, Yang C, Zheng S, Tang L, Zhou C, Qian G, Huang Y, Yu W, Li H, Wang Y, He A, Shen Z, Bao Q, Hua Y, Bai H, Zhao J, Li X, Dai X, Zhang J, Hu H, Yao Y. First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001. Clin Cancer Res, 2023, doi: 10.1158/1078-0432.
- Ding X, Liu Y, Zhang Y, Liang J, Li Q, Hu H, Zhou Y#. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study. Anticancer Drugs, 2023, doi: 10.1097/CAD.0000000000001482.
- Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z, Wang Y, Zhang Z, Yuan T, Ding X, Tang L, Zhang J, Yin J, Huang Y, Yu W, Wang Y, Zhou C, Su Y, He A, Sun Y, Shen Z, Qian B, Meng W, Fei J, Yao Y, Pan X, Chen P, Hu H. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun, 2020, doi: 10.1038/s41467-020-20059-6.
- 01/01/2022-12/31/2024
National Natural Science Foundation of China (youth project), ¥300,000, 82102866
The mechanism of TLR7 agonist activating MEG3/miR-185-5p/FABP4 pathway regulating lipid metabolism and promoting M1 polarization in osteosarcoma macrophages Role: Project leader
